Cd80 Cd86
Cd80 Cd86 - Related Videos
03:47
Generation of Immature, Mature, and Tolerogenic Dendritic Cells from Monocytes
0 Views •
2025
This video demonstrates the generation of immature, mature, and tolerogenic dendritic cells, or DCs, from human monocytes. The incubation of monocytes with growth factors and cytokines leads to the production of immature DCs. In response to immune regulatory molecules, immature DCs differentiate into tolerogenic and mature DCs.
06:09
Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
0 Views •
Cited by 38 •
2016
Immature dendritic cells can be selectively differentiated into tolerogenic or mature dendritic cells to regulate the balance between immunity and tolerance. This work presents a means to generate from immature monocyte derived dendritic cells (moDCs), in vitro tolerogenic and mature moDCs that differ in metabolic phenotypes.
03:35
Flow Cytometry-Based Analysis of Dendritic Cell Activation Using Immune Complexes
0 Views •
2025
This video demonstrates a protocol for assessing the activation of dendritic cells using immunoglobulin G (IgG)-coated tumor cells. Dendritic cells internalize the IgG-coated tumor cells, process the tumor antigens, and present them on the surface through MHC-II molecules, along with the co-expression of the costimulatory molecule CD86. These dendritic cells then undergo MHC-II and CD86-targeted immunostaining and flow cytometry analysis to identify their activation state.
04:13
An Adjuvant Therapy in a Mouse Model with an Incompletely Resected Subcutaneous Tumor
0 Views •
2025
This video illustrates testing of adjuvant or additional therapy in a mouse model with incompletely resected subcutaneous tumors. The partially tumor-resected mouse is treated with an antibody targeting the anti-cytotoxic protein of T regulatory cells, potentially reducing tumor regrowth and suggesting effective adjuvant therapy.
09:32
Time-Lapse Imaging of Antibody-Driven Macrophage Phagocytosis of Green Fluorescence Protein–Labeled Triple-Negative Breast Cancer Cells
0 Views •
2026
This protocol describes a time-lapse live-cell imaging method to visualize antibody-dependent macrophage phagocytosis of green fluorescent protein–labeled triple-negative breast cancer cells using peripheral blood mononuclear cell–derived macrophages and an automated microscope.
FAQs
The outcome depends on which receptor engages these costimulatory molecules. Once the T-cell receptor recognizes presented antigen, interaction with CD28 reinforces T-cell activation. Binding to CTLA-4 instead limits the response and supports immune regulation. Comparing these receptor-linked outcomes helps researchers study how adaptive immunity balances effective activation with preservation of immune tolerance.
Expression levels provide context for interpreting antigen-presenting-cell behavior. Dendritic cells, macrophages, and B cells can display these molecules, but their expression changes as cells become activated and respond to inflammatory signals. Consequently, measurements are most informative when considered alongside the cell type and its activation state rather than treated as isolated molecular markers.
In infection research, the CD80/CD86 system connects antigen-presenting-cell activity with downstream T-lymphocyte responses. Expression can be examined as part of a host response to pathogens, while CTLA-4 provides a context for understanding limitation of immune activity. This makes the molecules relevant to protective adaptive immunity as well as mechanisms that help prevent excessive responses.
Flow cytometry, microscopy, and related assays can measure CD80 and CD86 on immune cells. The selected approach allows investigators to evaluate the presence or distribution of these membrane proteins in relevant samples. Interpreting measurements alongside cellular activation and inflammatory conditions can help connect molecular expression with broader changes in immune-cell function.
A practical study design begins by identifying the immune-cell population and the research question, then selecting flow cytometry, microscopy, or another suitable assay to assess CD80 and CD86. Results can support comparisons of immune-cell function or host responses under different activation or infection-related conditions. The measurements are therefore interpreted as indicators of immune regulation, not isolated outcomes.
These molecules serve as useful endpoints in studies of autoimmune mechanisms and immunomodulatory therapies. In autoimmunity, investigators can examine how costimulatory and regulatory signaling relates to disruption of immune tolerance. In therapeutic research, measuring CD80 and CD86 helps assess pathways that may strengthen or restrain immune responses and supports evaluation of potential immunomodulatory targets.